Evidence map›Paper›PMID 37326108›Full record

ArticleOncology reports2023

Inhibition of protein arginine deiminase II suppresses retinoblastoma in orthotopic transplantation in mice.

Sojin Kim, Yong Keun Song, Chang Sik Cho, Hyo Jung Kim, Sungsoon Fang, Dong Hyun Jo, Hyunkyung Kim

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Citrullination in tumor immunity and therapy.The Journal of clinical investigation · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Sojin Kim *Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul 02841, Republic of Korea.
Yong Keun Song *Department of Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Chang Sik ChoFight against Angiogenesis‑Related Blindness Laboratory, Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.
Hyo Jung KimDepartment of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Sungsoon FangSeverance Biomedical Science Institute, Gangnam Severance Hospital; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul 06273, Republic of Korea.
Dong Hyun JoDepartment of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Hyunkyung KimDepartment of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul 02841, Republic of Korea.
Seoul National University · KRKorea University · KRGangnam Severance Hospital · KRSeoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapies are used for treating retinoblastoma; however, numerous patients suffer from recurrence or symptoms due to chemotherapy, which emphasizes the need for alternative therapeutic strategies. The present study demonstrated that protein arginine deiminase Ⅱ (PADI2) was highly expressed in human and mouse retinoblastoma tissues due to the overexpression of E2 factor (E2F). By inhibiting PADI2 activity, the expression of phosphorylated AKT was reduced, and cleaved poly (ADP‑ribose) polymerase level was increased, leading to induced apoptosis. Similar results were obtained in orthotopic mouse models with reduced tumor volumes. In addition, BB‑Cl‑amidine showed low toxicity

Indexed as

Retinal NeoplasmsRetinoblastomaAnimalsDisease Models, AnimalHumansMiceMutationProtein-Arginine DeiminasesProtein-Arginine DeiminasesAKT phosphorylationBB‑Cl‑amidineE2 factorprotein arginine deiminase IIretinoblastoma

Identifiers

PMID37326108
PMCPMC10285604
OpenAlexW4380487741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.